PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(02): 127-130
DOI: 10.1055/s-0041-1723120
Original Article: Supportive and Palliative Care

Assessment of Oral Anticancer Medication Adherence: A Survey from a Tertiary Cancer Center

Balaji Ramachandiran
1   Department of???, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India
,
Biswajit Dubashi
2   Department of Oncology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India
,
Smita Kayal
3   Department of Medical Oncology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India
,
Vikas Menon
4   Department of Psychiatry, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India
,
K. Yuvaraj
5   Department of Preventive and Social Medicine, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India
,
C. Deepika
5   Department of Preventive and Social Medicine, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India
,
Deepa Francis
1   Department of???, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India
,
Deeksha Debbarma
1   Department of???, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India
,
Devika S. Nair
1   Department of???, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India
› Institutsangaben Funding Nil.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Background Adherence to oral anticancer medication is important in cancer chemotherapy, with the advent of many oral anticancer regimens to ensure adequate cytologic response. Literature on adherence to oral anticancer therapy in India is very less.

Materials and Methods This is a cross sectional analytical study consisting of all fit patients > 18 years of age taking oral anticancer therapy, with or without intravenous (IV) chemotherapy. Adherence was determined using Morisky–Green–Levine (MGL) scale, and factors affecting adherence details about cancer and treatment were obtained. All fit patients were recruited. Information was obtained using Tamil questionnaire and pro forma.

Observation Of 152 patients, only 111 patients were found to be adherent to treatment. The mean age of the study population was 49.03 ± 13.48 years. Only 12.5% of patients were aware of the diagnosis, treatment, and outcome. The study population consisted mainly of patients with chronic myeloid leukemia, colorectal carcinoma, breast carcinoma, and stomach carcinoma, which amounted for 78.3% of the study population. Bivariate analysis concluded that duration of treatment, adverse drug reaction (ADR), duration of oral anticancer drug intake in a month, coadministration with IV anticancer drugs, and frequency of drug intake (anticancer drug) were significant factors affecting drug adherence. Multivariate analysis of the above variables was insignificant, but ADR tended toward significance.

Conclusion Drug adherence plays a major role in treatment outcome in cancer patients. ADR was independently associated with decreased drug adherence. Key interventions which should include counseling and behavioral modifications will reduce nonadherence.

Keywords

cancer - chemotherapy - drug adherence


Publikationsverlauf

Artikel online veröffentlicht:
30. September 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Urquhart J. Noncompliance: The ultimate absorption barrier. In: Prescott LF, Nimmo WS, eds. Novel Drug Delivery and its Therapeutic Application. New York: Wiley 1989: 127-37
  • 2 Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11 (06) 1189-1197
    CrossrefPubMedSuche in Google Scholar
  • 3 Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94 (09) 652-661
    CrossrefPubMedSuche in Google Scholar
  • 4 Nilsson JL, Andersson K, Bergkvist A, Björkman I, Brismar A, Moen J. Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care (Engl) 2006; 15 (03) 235-237
    CrossrefPubMedSuche in Google Scholar
  • 5 Ganesan P, Sagar TG, Dubashi B. et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011; 86 (06) 471-474
    CrossrefPubMedSuche in Google Scholar
  • 6 daCosta DiBonaventura M, Copher R, Basurto E, Faria C, Lorenzo R. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits 2014; 7 (07) 386-396
    PubMedSuche in Google Scholar
  • 7 Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24 (01) 67-74
    CrossrefPubMedSuche in Google Scholar
  • 8 Marin D, Bazeos A, Mahon FX. et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28 (14) 2381-2388
    CrossrefPubMedSuche in Google Scholar
  • 9 Geissler J, Sharf G, Bombaci F. et al. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol 2017; 143 (07) 1167-1176
    CrossrefPubMedSuche in Google Scholar
  • 10 Noens L, Hensen M, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica 2014; 99 (03) 437-447
    CrossrefPubMedSuche in Google Scholar
  • 11 Greer JA, Amoyal N, Nisotel L. et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist 2016; 21 (03) 354-376
    CrossrefPubMedSuche in Google Scholar
  • 12 Timmers L, Boons CC, Kropff F. et al. Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncol 2014; 53 (02) 259-267
    CrossrefPubMedSuche in Google Scholar
  • 13 Veronesi A, Pizzichetta MA, Ferlante MA. et al. Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment. Tumori 1998; 84 (03) 372-375
    CrossrefPubMedSuche in Google Scholar
  • 14 Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001; 19 (02) 322-328
    CrossrefPubMedSuche in Google Scholar